Literature DB >> 28573432

Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.

David A Schoenfeld1,2,3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28573432     DOI： 10.1007/s40265-017-0760-y

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  3 in total

1.  Assessing survival benefit when treatment delays disease progression.

Authors:  David A Schoenfeld; Dianne M Finkelstein
Journal:  Clin Trials       Date:  2016-02-22       Impact factor: 2.486

2.  Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.

Authors:  Stefan Michiels; Everardo D Saad; Marc Buyse
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Authors:  S Michiels; L Pugliano; S Marguet; D Grun; J Barinoff; D Cameron; M Cobleigh; A Di Leo; S Johnston; G Gasparini; B Kaufman; M Marty; V Nekljudova; S Paluch-Shimon; F Penault-Llorca; D Slamon; C Vogel; G von Minckwitz; M Buyse; M Piccart
Journal:  Ann Oncol       Date:  2016-03-08       Impact factor: 32.976
  3 in total
  1 in total

1.  Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors".

Authors:  Stefan Michiels; Everardo D Saad; Marc Buyse
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.